Six Gladstone Scientists Named Among World’s Most Highly Cited Researchers
Honorees rank among the top 1 percent of researchers globally, reflecting Gladstone’s broad scientific influence.
Six investigators from Gladstone Institutes have been named to the 2026 list of Highly Cited Researchers, which celebrates scientists who demonstrate significant and broad influence in their fields. For an independent institute with 36 highly curated laboratories, having six honorees represents a remarkable concentration of global scientific leadership.
“This recognition underscores the extraordinary impact of Gladstone’s investigators,” says Deepak Srivastava, MD, president of Gladstone. “Their work is not only advancing our fundamental understanding of human biology, it’s laying the groundwork for transformative treatments across cancer, neurological disorders, and immune-related diseases.”
To make the list, scientists must author peer-reviewed papers that rank in the top 1 percent by citations for their field and publication year over the past 11 years. The rigorous evaluation and selection process draws on data from the Web of Science Core Collection, a citation database managed by Clarivate. The list is then refined using additional metrics that measure broad scientific influence and pioneering contributions to emerging areas of research.
“These researchers continue to shape the future of science, technology, and academia globally and deliver innovation that drives societal progress,” says David Pendlebury, head of research analysis at Clarivate’s Institute for Scientific Information.
The scientists from Gladstone who are named on the 2026 list are:
Ryan Corces, PhD
Corces studies how genetic and environmental factors can impact the risk of developing neurodegenerative diseases such as Alzheimer’s and Parkinson’s. While genetic mutations modify genes directly, other factors such as previous illnesses, exposure to environmental chemicals, or simply the process of aging can leave lasting imprints on the epigenome—the DNA sequences and proteins that control how genes are expressed. Using computational biology, large-scale genetic screens, and other technologies, Corces probes cells derived from patients with the aim of understanding the many facets of disease risk and developing novel therapeutic interventions. Corces is an assistant investigator at Gladstone and associate professor of neurology at UC San Francisco.
Jennifer Doudna, PhD
Doudna is a global innovator in gene editing, and was awarded the 2020 Nobel Prize in Chemistry for her role in the development of a precise and versatile genome-editing method called CRISPR-Cas9. This breakthrough opened the floodgates of possibility for human and non-human applications of gene editing, including for the treatment or cure of sickle cell disease, muscular dystrophy, and HIV. In addition to her scientific achievements, Doudna is a leader in public discussion around the ethical implications of gene editing and an advocate for thoughtful approaches to policies around the technology’s use. Doudna is a senior investigator at Gladstone, a professor at UC Berkeley, and an investigator at Howard Hughes Medical Institute. She is also the founder of the Innovative Genomics Institute at UC Berkeley, UCSF, and UC Davis.
Alex Marson, MD, PhD
Marson and his cross-disciplinary team have expanded our understanding of the genetic circuits that control how the human immune system functions. He has pioneered new gene-editing technologies that offer faster, cheaper, and more precise ways to re-write DNA in immune cells so they can be engineered to treat a wide range of diseases. For example, his group is working to develop cells that can recognize and eliminate cancer, fend off infections such as HIV, and reduce inflammation in autoimmune diseases. Marson is the Connie and Bob Lurie Director of the Gladstone-UCSF Institute of Genomic Immunology and center director of the Parker Institute for Cancer Immunotherapy at Gladstone Institutes. He is also a professor at UCSF and director of the CRISPR Cures for Cancer Initiative—a joint effort between Gladstone, UCSF, and the Innovative Genomics Institute.
Katie Pollard, PhD
Pollard and her team leverage data science and AI to decode how genomes work, evolve, and break in disease. Their analyses of massive sets of genomic and epigenomic data include investigating human genetic variation, understanding what makes humans unique compared with other species, and characterizing the genomic diversity of the human microbiome. An evolutionary focus, coupled with rigorous statistical methods and bioinformatics tool development, gives her lab a unique perspective on human biology and disease. Pollard is the L.K. Whittier Director of the Gladstone Institute of Data Science and Biotechnology. She is also a UCSF professor and an investigator at Biohub.
Kole Roybal, PhD
Roybal uses synthetic and chemical biology to program immune cells into smarter, safer cancer-fighting therapies. Focusing on engineered T cells known as CAR-T cells, his lab works to improve every step of their mission: helping them accurately detect cancer cells, launch a targeted attack, and eliminate tumors without harming healthy tissue. He also investigates how immune cells communicate and coordinate as a team to mount an effective response against disease. Roybal is an affiliate investigator at Gladstone. He is also a professor of microbiology and immunology at UCSF, an investigator with Biohub, and director of the Parker Institute for Cancer Immunotherapy.
Matt Spitzer, PhD
Spitzer studies how cancer interacts with the immune system, focusing on key defenders like T cells and dendritic cells. By combining laboratory experiments with powerful data analysis tools that examine immune cells one by one, his team has revealed that cancer alters immune function not just inside tumors, but across the body. He’s using these insights to make cancer immunotherapies work better for patients. Spitzer is an affiliate investigator at Gladstone, as well as a professor in the Departments of Otolaryngology–Head and Neck Surgery and of Microbiology and Immunology at UCSF and a Werbe Endowed Professor in Head and Neck Oncology at UCSF. In addition, he is an investigator with the Parker Institute for Cancer Immunotherapy and the Arc Institute.
For Media
About Gladstone
Gladstone Institutes is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. Established in 1979, it is located in the epicenter of biomedical and technological innovation, in the Mission Bay neighborhood of San Francisco. Gladstone has created a research model that disrupts how science is done, funds big ideas, and attracts the brightest minds.
Up Next
Rethinking ‘Exhausted’ T Cells: Gilbert Herrera Named Inaugural Ellen & Bernard Marson Fellow
The fellowship provides three years of funding for graduate students pursuing groundbreaking immunology research.
Scientists Decode Gene Circuits of Human Immunity, Fueling New Era of Disease Research
An unprecedented map of 22 million immune cells provides the functional rulebook for virtual biology and next-generation immunotherapies.
New Toolkit Turns Macrophages Into Better Cancer Fighters
Gladstone and UCSF scientists developed a method to genetically edit myeloid cells, immune cells that act as the body’s first responders.
Misfolded DNA Blueprint: A New Origin for Genetic Disease
Gladstone researchers found losing just one copy a particular gene can disrupt heart development and lead to congenital heart disease.
Get Involved
Join the Team
Our people are our most important asset. We offer a wide array of career opportunities both in our administrative offices and in our labs.
Open PositionsPartner With Us
Discoveries don’t stay in our labs. Gladstone facilitates spinout companies to advance promising therapies, shortening the path between scientific discovery and helping real patients.
Learn MoreGive
Your gift to Gladstone will allow our researchers to pursue high-quality science, focus on disease, and train the next generation of scientific thought leaders.
Donate Now